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To respond to environmental changes, cells must transfer
information concerning their environment across their imper-
meable membranes. One solution to this problem involves three
proteins: a receptor which detects information outside the cell,
an effector molecule which alters the intracellular environment,
and a guanine nucleotide regulatory protein (G protein) which
couples the receptor to the effector molecules. The features of
this system that make it particularly useful for transmembrane
signalling are that signals can be amplified at several steps, and
that the transfer of information is unidirectional. This three
protein system is used by organisms ranging from yeast to
mammals, and is versatile, responding to signals from light and
smell to hormones and neurotransmitters. The signals regulate
rapidly occurring events such as action potentials, and long-
term events such as growth and development [reviewed in 1—61.
In the kidney, G proteins are involved in the action of hormones
such as PTH, vasopressin, and angiotensin II, and the activa-
tion of second messenger systems such as adenylyl cyclase,
phospholipases, and ion channels. This paper examines the
basic mechanisms by which G proteins work, focusing on the a
chains, the general signalling pathways in which they are
involved, and finally considers how what has been learned
about their function can be applied to understanding the kidney.
G proteins are heterotrimeric proteins composed of a, /3, and
y subunits which transfer information from receptors to effec-
tors through cyclic changes in conformation driven by GTP
binding and hydrolysis. The various G proteins are character-
ized by their a subunits because the a subunits are the most
diverse, and are generally believed to be responsible for the
specificity of receptor and effector interactions. The a subunits
are also responsible for GTP binding and hydrolysis, reversible
interactions with 13y subunits, and are the substrates for ADP-
ribosylation by cholera and pertussis toxins. To date, evidence
for sixteen a subunits exists (Table I), all of which show
striking structural similarity to one another [1—81. When com-
pared to a, the other a subunits which have been completely
cloned (a01f, a0, a113, a, and a) are 42 to 46% homologous, but
if a is left out of the comparison, the homology ranges from 60
to 72% [2, 71.
The /3 and y subunits are less well understood, but are
believed to be important for membrane interactions and recep-
tor coupling, and may in some systems be able to activate
effectors. To date, four /3 and up to four y subunits have been
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identified [MI Simon, personal communication]. The /3 subunits
are similar with only 15% divergence at the amino acid level [8,
9, M.I. Simon, personal communication]. Transducin y and
brain G0 and G-associated y are 55% homologous [10, 11].
Although fry subunits purified from retina and brain inhibit
cyclase with different efficiency, the functional differences
among the /3 and y subunits from brain have not been deter-
mined [11].
G proteins are implicated in a signalling pathway by one or
more of several criteria, activation of the pathway by nonhy-
drolyzable GTP analogs or A1F4, inhibition by GDPI3S, sen-
sitivity to pertussis or cholera toxins, stimulation of GTP
hydrolysis by the receptor agonist, and regulation of receptor
affinity for agonist by guanine nucleotides [2, 3]. Although these
criteria serve to distinguish G protein-dependent signalling
pathways from others such as tyrosine kinase receptors, or
ligand-gated ion channels, they frequently do not help to
distinguish among the many possible G proteins.
Only two systems have been well characterized at the mo-
lecular level. Most of the detailed biochemical information on G
protein action comes from the study of the retinal rhodopsin-
transducin-cGMP phosphodiesterase system, and the G-ade-
nylyl cyclase system. In the retinal system, large amounts of the
three principal components—rhodopsin, the receptor; transdu-
cm, the G protein; and cGMP phosphodiesterase, the effec-
tor—can be purified relatively easily in large quantities, allow-
ing detailed biochemical studies [5, 6, 12]. The G-adenylyl
cyclase system has been accessible to study despite small
quantities of protein because a mutant cell line lacking G,
Cyc—, allowed its identification, purification, and characteriza-
tion by reconstitution [2, 3].
For the other a chains, less precise information is available
for a number of reasons. Multiple a chains are present in a
single tissue or cell type, they are similar biochemically and
difficult to purify to homogeneity, and appropriate mutant cell
lines analogous to Cyc— for reconstitution do not exist. Addi-
tional problems in identifying the signalling pathways served by
a specific G protein are that the components of signalling
pathways are present in small quantities in most tissues, and the
pathways are complex. Multiple receptors can activate a single
G protein, a single G protein can activate multiple effectors, and
multiple G proteins may activate the same effectors. Progress
has been made with antisera and reconstitution of purified
proteins into relatively "complete" systems such as whole cells
and membrane patches, but the results are not as clean as for
transducin and G.
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The guanine nucleotide-dependent activation cycle
G proteins carry information from receptors to effectors by
exchanging bound GDP for GTP, and assuming a new, active
conformation (Fig. 1). Information is transferred because the a
chain interacts with different proteins or sets of proteins in the
GDP and GTP-bound states, and the cycle is unidirectional. In
the GDP-bound conformation, the a subunit binds with high
affinity to f3y, but is unable to activate effectors. In the
GTP-bound conformation, the a chain has a decreased affinity
for /3y, but binds to, and activates effectors. Transition of the a
chain from its inactive, GDP-bound state to active, GTP-bound
state requires the release of GDP. This process is catalyzed by
interaction with an activated (ligand-bound) receptor. Once
GTP has replaced GDP in the binding site, the a subunit
dissociates from f3y, and activates the effector. The a subunit
remains activated until it hydrolyses GTP to GDP. The cycle is
unidirectional because a chains are unable to synthesize GTP
from GDP [12].
The steps in the a chain activation cycle are shown in Figure
I. In reaction 1, aGDP/3y interacts with an activated receptor
(R*) to produce the transient complex R*a/3y with no guanine
nucleotide bound. The a chain can then bind either GDP
(reversal of reaction 1) or GTP (reaction 2), but the reaction
proceeds to the right because the products of reaction 2 are
"consumed" by progression of the cycle, and because the
concentration of GTP usually exceeds that of GDP in the cell
[l—3].
Reactions 1 and 2 provide the basis for two "assays" for G
protein involvement in signalling systems. Reaction I is the
principle control point for activation of effector systems [1—6].
ADP ribosylation of several a chains (a13, a0, and a) by
pertussis toxin blocks the ability of receptors to catalyze step I
which leads to pertussis toxin-dependent inhibition of a process
[1—6, 13, 14]. The transient complex R*aI3y allows detection of
guanine nucleotide-dependent shifts in receptor affinity for
agonists (discussed below).
In reaction 2, GTP, which is usually in excess over GDP,
binds the empty guanine nucleotide binding pocket of the a
chain in the R*a/3y complex to yield R* and aGTP/37. A single
R* can activate many U proteins which permits amplification of
signals at the level of G protein-receptor interaction [4—6].
Reaction 3 is the GTP-induced conformational change in the
a subunit that results in dissociation of aGTP from /3y and
permits association with, and activation of effectors. This
reaction requires Mg [2, 15, 16]. Whether or not true dissocia-
tion of subunits occurs in membranes is not clear at this point,
but certainly the affinity of a for (3y decreases. Purified,
preactivated a subunits (a chains that have been purified, and
usually activated with a nonhydrolyzable GTP analog) are
sufficient to activate effectors in reconstituted systems [1—6].
This reaction is reversible by the addition of excess f3y [2, 15].
The conformational change in the a subunit induced by GDP or
GTP which results in dissociation of a/3y from R* is distinct
from reaction 3 [161.
In reaction 4, the activated a subunit hydrolyses GTP to
GDP, reverts to its inactive conformation, and dissociates from
the effector. This reaction is irreversible because a chains are
unable to synthesize GTP from GDP and P. [12]. The irrevers-
ibility of this reaction makes G protein-dependent signalling
systems unidirectional. Varying the rate of GTP hydrolysis can
result in altered signal transduction. ADP-ribosylation of G by
cholera toxin and mutations in G can result in increased cAMP
levels and altered tissue function such as diarrhea in the
intestine, and some pituitary tumors [6, 171. Cholera toxin
treatment of transducin causes prolonged activation of the
retinal cGMP phosphodiesterase [5]. Although GTP hydrolysis
is an important mechanism for signal termination, it is probably
not the only one. In the retina and some patch clamp studies,
the removal of agonist results in cessation of the signal too
rapidly to be explained by GTP hydrolysis alone [4]. Finally, in
reaction 5, aGDP reassociates with j3y, and aGDP/3yis ready to
begin the cycle again.
Several points from the activation cycle of G proteins should
be emphasized because they are important for understanding
data generated by toxin labelling and receptor binding experi-
ments. Many G protein-coupled signaling systems are sensitive
to pertussis toxin. In the absence of R*, reaction 1 proceeds at
different rates for different a chains. In the case of transducin,
GDP-GTP exchange absolutely requires interaction with an
activated receptor (light-activated rhodopsin). The experimen-
tal demonstration of this fact is that nonhydrolyzable GTP
analogs do not activate transducin in dark-adapted rod outer
segments [5]. Tight binding of GDP to transducin in the dark
(absence of activated rhodopsin) with a negligible spontaneous
rate of guanine nucleotide exchange is what one would hope for
in the visual system where spontaneous GDP-GTP exchange
would be interpreted as photons or visual "noise" [5, 6]. For G
and the adenylyl cyclase system, the requirement for R* is
much less strict, with detectable spontaneous guanine nucleo-
tide exchange. The basal rate of guanine nucleotide exchange
results in time-dependent activation of cyclase by nonhydrolyz-
able guanine nucleotide analogs [2].
Because pertussis toxin blocks the interaction of a/3y-GDP
with R*, PT treatment would not be expected to alter the basal
rate of activation of a given system, but would inhibit activity to
the extent that it requires interaction with an activated receptor.
PT completely blocks activation of transducin, but in other
systems, other effects have been observed [5, 13, 14]. PT may
prevent agonist-dependent activation of a pathway while allow-
ing a basal level of activity to persist, or may apparently turn off
the pathway completely, with inability to activate it with
nonhydrolyzable guanine nucleotide analogs. These findings
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Fig. 1. The activation cycle of G proteins
converts inactive cr/3 y-GDP to active cr-GTP.
Details are in the text. a and f3y represent
the subunits of the G protein heterotrimer.
R and R* represent the inactive and active
forms, respectively, of the receptor. PT and
CT represent the points at which ADP-
ribosylation of the a chain by pertussis or
cholera toxins affect the cycle.
indicate that a chains which are PT substrates exist that have
high and low spontaneous rates of guanine nucleotide ex-
change. Additionally, when one observes PT inhibition of a
system in the absence of added receptor agonist, one must
wonder if agonist is somehow present in the system, or if the
receptor-G protein interaction is "leaky" and can proceed in
the absence of receptor agonist [14, Linder, personal commu-
nication].
G protein involvement in signaling systems can be demon-
strated by a guanine nucleotide-dependent shift in receptor
affinity for agonist. The R*af3y complex (no guanine nucleotide
bound) is normally short-lived in cells where guanine nucleo-
tides are present. In membrane preparations guanine nucleo-
tides can be removed, and the complex stabilized. Under these
conditions, R*cr/3y has a higher affinity for receptor agonist
(hormone) than R* alone (not bound to a/3'y) [1, 2]. When either
GDP or GTP (and analogs) are added (reversal of reaction 1, or
reaction 2), the complex dissociates leaving R* with a lower
affinity for agonist [1, 21.
The A1F4 ion can activate G proteins without benefit of a
receptor, or need for guanine nucleotide exchange. Activation
of an a chain requires only that GDP is already bound. A1F4
"looks" like the y phosphoryl of GTP, so in the presence of
GDP, the presence of A1F4 results in the equivalent of GTP.
As would be expected, A1F4 nonspecifically activates all of
the GTP-dependent signalling systems present in a cell or
membrane preparation [18, 19].
G protein structure
G proteins are able to move through their activation cycle and
associate specifically with a variety of other proteins because of
their structure. Consequently, understanding G protein action
requires an understanding of their structure, information on the
structure of a chains has come from molecular cloning and
mutagenesis, biochemical studies, and analogy to structurally
related proteins about which more detailed information is
available. All of the a chains that have been cloned so far share
regions of homology and divergence. Presumably the homolo-
gous regions perform functions which all of the proteins have in
common, such as GTP binding and hydrolysis, and regions of
divergence perform individual functions, such as interaction
with distinct receptors and effectors. The principal functional
domains of a chains with which we will be concerned are those
for binding and hydrolyzing guanine nucleotides, and those
which interact with receptors, effectors, and /3y.
Guanine nucleoride binding domain
The guanine nucleotide binding domain of 0 protein a chains
must perform several functions. It must release GDP in the
presence of receptors (possibly representing a conformational
change); it must bind GTP, and communicate that information
to another part of the molecule through a conformational
change; and it must hydrolyze GTP to GDP, release the y
phosphate, and return to its original conformation. This domain
of a chains resembles that of two other proteins, p21ras and the
bacterial elongation factor EF-Tu, whose structures have been
defined by in vitro mutagenesis and X-ray crystallography [3,
20, 21]. G protein a chains contain four limited stretches of
homology to p2lras and EF-Tu. These regions form four loops
which with Mg, coordinate the guanine nucleotide. Two of the
loops are of particular importance because they act as "switch"
regions, which are involved in guanine nucleotide-dependent
changes in conformation and GTP hydrolysis [20, 21, 161.
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result in a decreased rate of GTP hydrolysis, and give the
mutant forms of p2lras the ability to transform cells [22]. These
two mutations are the two most common ras mutations found in
human tumors [22]. Mutations in analogous regions in a5 (amino
acids 45-52, and 222-228) similarly result in alterations in GTP
hydrolysis and ability to change conformation in response to
djfferent guanine nucleotides [17, 23, 24]. Recently, a mutation
at Q227 has been described in a pituitary tumor which has an
altered cyclase phenotype [17]. To date, one a chain, a1 has
been described which differs from the consensus in the AA
45-52 region [25, 26]. a1 hydrolyses GTP more slowly than other
a chains [27].
The region of a chains which contains the arginine ADP-
ribosylated by cholera toxin in G5 and transducin appears to be
important for regulating the rate of GTP hydrolysis. ADP-
ribosylation of G5 and transducin by cholera toxin activates
these proteins by reducing the rate of GTP hydrolysis. Muta-
tions in G at this site (naturally occurring in pituitary tumors,
or made by site directed mutagenesis) lead to activation of the
protein due to a decreased rate of GTP hydrolysis [18, 23, 24].
The region which contains the CT ADP-ribosylation site has
some limited homology to GAP, the GTPase activating protein
which regulates GTPase activity of p2l, and may play the
same role in G protein a chains [28, 29].
Interactions with /3,'
In the process of activation and deactivation, a chains must
interact reversibly with 3y. a subunits have a high affinity for
/3,' in their GDP-bound forms, and a low affinity for 13,' in their
GTP-bound active forms, a chains can associate with receptors
only as a complex a-GDP/37 [1—6]. Additionally, it is only this
form of G proteins which can act as substrates for pertussis
toxin [13, 14]. Biochemical studies of transducin indicate that
the carboxy and amino termini of the a chain are involved in its
interaction with /3,' [30, 31]. Binding of /3,' by a chains alters a
chain conformation as demonstrated by the ability of excess
added /3,' to reverse GTPYS induced activation of G5, and to
regulate the affinity of a0 for GDP [2, 15]. In the presence of
physiologic concentrations of Mg, /3,' facilitated dissociation of
GDP from a leads to an apparent increase in the rate of GTP
hydrolysis [15].
Receptor interactions
To date, all of the receptors which activate G proteins which
have been cloned have the same general predicted structure:
seven transmembrane domains connected by alternating cyto-
plasmic and extracellular loops. These include /3, a, muscarinic,
serotonin, dopamine, and LH-hCG, receptors [4, 32]. On the
basis of mutations and biochemical studies in a number of
receptors, the third cytoplasmic loop (which contains positive
charges) and a portion of the C terminal cytoplasmic tail are
believed to interact with G proteins [4, 33]. Several regions of
the a chain or a/3y heterotrimer are important for receptor
contact. Evidence from multiple sources indicates that the
carboxy terminus of a chains is an important site for binding
receptors. The site ADP-ribosylated by pertussis toxin in the a
chains which are pertussis toxin substrates (a113, a0, and at) is
in the C terminus—a conserved cysteine four amino acids from
the end [2, 3j. Secondly, the Unc mutation in a5 which prevents
coupling of a5 to /3 adrenergic or PGE2 receptors is located in
this same region. Unc results in the substitution of proline for
arginine at the sixth amino acid position from the carboxy
terminus [34, 35]. Finally, the amino acid sequence of the
carboxy terminus of at is homologous to a region of arrestin, a
retinal protein that competes with at for binding to rhodopsin,
and is part of the turn off mechanism for vision [36].
Although the carboxy terminus of a chains is required for
productive coupling of receptors to U proteins, it is not the only
region that contributes to the specificity of this interaction.
Comparison of the sequences of the carboxy termini of a1, a0,
and a1 would predict that if the carboxy terminus were the sole
determinant of U protein receptor interactions, receptors which
recognize G- would also recognize transducin, and might couple
less well to G0. This is not the case, however, because a2
adrenoceptors couple much better to G. and U0 than to trans-
ducin [37]. These findings indicate that some other part of the a
chain or a/3y complex is involved in specifying the interaction
with receptors.
Effector interactions
Less is known in molecular terms about the interactions of G
proteins with effectors than with other components of the
signalling pathway because less detailed information is avail-
able on the structure of effectors. The two best characterized
systems, the retinal cGMP phosphodiesterase and adenylyl
cyclase, appear different in molecular details. In both, however,
the purified preactivated a chain is sufficient to activate the
effector. a activates the retinal cGMP phosphodiesterase by
interacting with (possibly dissociating) an inhibitory subunit.
Some evidence suggests that at may also interact directly with
the catalytic subunit of cGMP phosphodiesterase [4]. This
mechanism is unlikely because trypsinization which cleaves the
inhibitory subunit of cGMP phosphodiesterase can also cause
activation [5]. In contrast, as demonstrated by copurification
studies, active adenylyl cyclase is a complex of cyclase itself
and a5-GTP [2]. Studies using chimeric a chains, (the carboxy
terminal half of a5 and the amino terminal halves of a12 and at)
indicate that at least one important binding site for cyclase is in
the carboxy terminal half of the molecule [38].
The mechanism by which other G proteins interact with
effectors leading to activation of ion channels, phospholipases,
and inhibition of cyclase is not clear. Either all of the compo-
nents of a system have not been purified to homogeneity in
functional form, or when reconstituted, do not function as
expected. Regulation of these effectors may involve both a and
/3,' subunits.
Hormone-dependent inhibition of adenylyl cyclase is sensi-
tive to guanine nucleotides and pertussis toxin, indicating that a
G protein which is a pertussis toxin substrate is involved in the
pathway. In in vitro reconstituted systems added /3,' inhibits
G5-stimulated cyclase, while added, preactivated a1 is less
effective [1, 2]. Activation of a1 leads to "excess" /3,' subunits
in the membrane which then bind to activated a5, deactivating
it. These data predict that hormone-dependent inhibition of
cyclase should require the presence of a5. This is not the case,
however, because hormonal inhibition of forskolin-stimulated
cyclase is found in Cyc— cells which lack a5 [39, 40]. Conse-
quently, the molecular mechanism of hormone-dependent cy-
clase inhibition is unclear, but may involve a5-fry, direct
a1-cyclase interactions, or other mechanisms. An additional
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point is that the physiologic significance of cyclase inhibition
remains to be demonstrated.
In many tissues, ion channels are regulated by many factors
including membrane potential, intracellular Ca, external ligands
(hormones, neurotransmitters and drugs), and classic second
messenger pathways (protein kinases) [41—43]. A subset of
these ion channels appear to be regulated on two levels: through
the classic second messenger, protein kinase pathway (regula-
tion by phosphorylation-dephosphorylation mechanisms), and
through a more rapid, direct or "membrane delimited" system.
Activation of ion channels by G proteins has been demonstrated
primarily by patch clamp studies and microinjection of purified
subunits [41—54]. Regulation of K, Cl, Na, and Ca channels has
been shown to be sensitive to guanine nucleotides and pertussis
and cholera toxins (the specificity of ion channels for different a
chains will be discussed below), a subunits appear to be the
principal regulators of channels. Specificity of this interaction
has been demonstrated by the fact that a given ion channel is
regulated primarily by a single a chain, for example a1 but not
a0 or a5. f3y may also be involved with K channels in that either
component (a or j3y) can activate K channels when added to
inside-out patch preparations [47, 51, 531. At this point, the
relative importance of a versus f3y is controversial because of
apparent differences in the quantities of each component re-
quired, the concentration of each in the membrane, and the role
of detergents. Some data suggests that f3y may act through a
lipid second messenger and indirectly activate channels [51,
53—55]. These findings may be reconciled by one report which
indicates that J3y activates PLA2 [56]. Genetic data from yeast
suggests that at least in the signalling pathway for mating, /3)'
has an important function [57]. To date, the purified compo-
nents have not been reconstituted, so it is not clear if the
interaction is direct or through other membrane components.
Another unresolved issue in regulation of ion channels by G
proteins is the "turn off" mechanism. When agonist is re-
moved, activity of the channel ceases more rapidly than would
be expected if GTP hydrolysis were the only mechanism [4].
Understanding the precise role of G proteins in the regulation
of phospholipases has been difficult for many of the same
reasons it is difficult for ion channels. The situation is compli-
cated by the fact that multiple proteins have been isolated
which hydrolyze lipid or phospholipid precursors to inositol
phospholipids, diacylglycerol, or arachidonic acid [1—6, 58—62].
At least four "phospholipase C's" (inositol-specific phospholi-
pases) have been cloned, and evidence exists for multiple
phospholipase D's and A's. Since the end point in many assays
is the accumulation of one of these products, the identity of the
effector or how many effectors are involved is not known. In
many systems, activation of these enzymes occurs via the same
receptor types as cyclase inhibition, is guanine nucleotide
dependent, and may or may not be pertussis toxin sensitive. As
is the case with ion channels, the components of these systems
have not been successfully reconstituted in purified form,
although G proteins have been copurified with phospholipases
[631.
Specific chain functions
G5, the activator of hormone-sensitive adenylyl cyclase, was
the first G protein discovered. Many receptors, including those
for catecholamines, histamine, PTH, AVP, glucagon, PGE2 and
PGI2, activate a5. a5, like other G protein a chains, was felt to
activate only a single effector: cyclase. It is now clear that it
may regulate up to three effector systems in addition to cyclase.
a5 increases the frequency of opening of voltage-sensitive Ca
channels in heart muscle and decreases the frequency of
opening of Na channels [42, 45]. In S49 cells, a5 regulates Mg
uptake by a non cAMP-dependent mechanism [2]. Four distinct
cDNA clones for a5 have been identified which result from
alternative splicing of a single gene, and differ by fifteen or
sixteen amino acids [64]. On polyacrylamide gels, these four
forms resolve into two bands of apparent sizes of 45 and 52
kDa. a5 is present in virtually all mammalian tissues, although
the relative amounts of the two forms varies. Both the 52 and 45
kDa forms activate cyclase and Ca channels [41. They differ in
their affinities for GDP, but the physiologic significance of this
difference is not known [24, 65].
G, was originally thought to be a single pertussis toxin-
sensitive protein which mediated hormonal inhibition of cy-
clase. Molecular cloning has revealed at least three separate
"a1's" which fall into the 40 to 41 kDa size range, and are the
products of separate genes [66]. a11 and a13 migrate at 41 kDa,
and a12 migrates at 40 kDa on SDS-polyacrylamide gels [1—3].
The a1's are expressed in varying ratios in different cell types.
"G1' '-mediated signals are triggered by a number of receptors
including muscarinic, a, opiate, angiotensin II and AVP. The
fact that pertussis toxin blocks G-mediated inhibition of cy-
clase suggests that other pertussis toxin-sensitive processes
which are often activated coincidentally, (including stimulation
of phospholipases A2 and C and activation of K channels) might
also be mediated by "G1".
The "G1's" appear to activate multiple channels. In inside
out patches of atrial muscle from several species, purified
preactivated a1 are capable of activating K channels [41, 47,
67]. a1 effects on K channels may be tissue-specific, however,
because in cell-free patches from hippocampal neurons, the a1's
tested had no effect [68]. Patch clamp studies of A6 cells and
primary cultures of IMCD cells show that a,3 can activate Na
channels [48, 49]. a13 activates Cl channels in CCD cells [50]. In
neural tissue, the a1's inhibit Ca channel activity [46, 52].
At present, it is not clear to what extent the a1's have different
functions, or put another way, how specificity of G protein-
mediated signalling pathways is determined. The fact that
multiple receptor subtypes exist (such as muscarinic) which
may have specificity for different a chains and signalling path-
ways further complicates studies [1—6, 69—71]. A single "G1"
could couple a single receptor to multiple effectors, or multiple
"G1's" could interact with a single receptor class and each
activate a single effector. In one case, dopamine receptors
appear to have a relative preference for a12 over a,1 or a3 in a
reconstituted system [72]. Another possible solution to the
problem of specificity of information transfer is that cells may
provide organizational information not supplied by protein-
protein interactions alone. For example, platelet activating
factor (PAF) and thrombin stimulate phosphoinositide hydrol-
ysis in whole platelets, without altering cAMP metabolism, but
in membrane preparations where presumably cytoarchitecture
is disrupted, both agents inhibit cyclase and stimulate P1
production [731. Additionally, different receptor subtypes ap-
pear to couple to different "G1's", with the "G1" coupling to
one or multiple effectors. Expression of different muscarinic
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receptor subtypes in Chinese hamster ovary (CHO) cells pro-
duces different responses to acetylcholine. HML and HM4
receptors stimulate P1 turnover and activate K channels, while
HM2 and HM3 receptors inhibit cyclase [74]. Consequently, in
CHO cells different G proteins appear to mediate inhibition of
cyclase and P1 turnover through different receptor subtypes.
Whether or not this pattern will be generalized to other systems
is not clear.
G0 was first identified as a 39 kDa pertussis toxin substrate
from brain that copurified with a1 [21. Biochemical and molec-
ular biologic studies have now demonstrated that two forms of
a0 exist due to differential splicing of the same gene [8, 75, 761.
The functional differences between the two forms of a0 remain
to be demonstrated, a0 is the predominant G protein in brain,
although it can be found in other tissues at lower concentra-
tions. a0 is distinguished from the a1's by its size, location of its
gene on a different chromosome, and its inability to inhibit
cyclase [2, 31. The problems in assigning functions to the at's
also apply to a0. The potential receptors include opiate, mus-
carinic, and neuropeptide Y, and the potential effectors include
activation of phospholipase C and inhibition of Ca channels [46,
77]. In the last example, purified a0 was microinjected into
dorsal root ganglion cells and was able to reconstitute the
complete neuropeptide Y signalling pathway for Ca channel
inhibition in pertussis toxin-treated cells, but not that for
bradykinin [46]. The a1's were less selective. Whether or not a0
can activate K channels is currently controversial [4].
G is a relatively new a chain first detected by cDNA cloning,
whose function remains unknown [25, 26]. This a chain di-
verges from the others in one of the highly conserved sequences
in the guanine nucleotide binding domain, and is not a substrate
for either cholera or pertussis toxin. It is expressed primarily in
nervous tissue, adrenal medulla, and platelets, although in small
amounts in other tissues. Functionally, a has a lower rate of
spontaneous guanine nucleotide exchange, and lower GTPase
activity than other a chains studied to date [27]. These findings
suggest that a may behave differently from other a chains in
signalling pathways.
A number of new a chains undoubtedly exist, and remain to
be characterized. Many receptors activate signalling pathways
which include G proteins based on sensitivity to guanine
nucleotides and ALF4, and which demonstrate shifts in recep-
tor affinity for agonists in response to guanine nucleotides, but
which are insensitive to bacterial toxins (many of these recep-
tors also mediate processes which are sensitive to pertussis
toxin). The receptors include those for angiotensin II, a ago-
fists, bradykinin, PAF, PGE2, substance P, thrombin, bombe-
sin, AVP, acetylcholine, and TRH, while the effectors include
phospholipases and K channel inhibition. Recent cloning using
the polymerase chain reaction has led to partial sequences for
five previously unidentified a chains, all of which lack the
C-terminal cysteine which is ADP ribosylated by pertussis toxin
[7, M.I. Simon, personal communication]. They have a wide
tissue distribution, and message for four is found in RNA
prepared from whole kidneys. Just as "G1" inhibits adenylyl
cyclase, other G proteins may work by inhibiting other effec-
tors, providing similar dual regulation.
Several important issues in the biology of G proteins have not
been discussed, including interaction with other signalling sys-
tems, membrane localization, post-translational modification,
tissue-specific expression and regulation of gene expression.
These issues are complex, and progress is being made, but firm
conclusions are not possible now. G protein-dependent signal-
ing systems clearly interact with each other and tyrosine
kinases. Some data suggest that systems as divergent as the
insulin receptor, GM-CSF-1 receptor, and the PDGF receptor
may work at least in part, through 0 proteins [78—80]. a chains,
including at, a, and a are substrates for conformation-depen-
dent phosphorylation by protein kinase C. Protein kinase C
appears to block inhibition of cyclase, but effects on other
components of the "G" signalling system cannot be excluded
[8 1—831. How G proteins attach to membranes and where they
are localized remain controversial, although one report shows
sorting of different a1' s to different membranes in polarized cells
[84—87]. Post-translational modification may be important for
the a1's, a0 and a in that they are myristoylated near the NH2
terminus [88, 891. This acylation is important in allowing the a
subunits to attach to cell membranes. By analogy, p2lras
proteins do not function normally if not properly fatty acid
modified [90]. Acylation of a has not been demonstrated [88,
89]. Tissue-specific expression is clear for two a chains, a01 and
a, but remains unclear for the rest, where the sensitivity and
specificity of detection methods (antibodies and nucleic acid
probes) is a problem [5, 91]. Differential a chain expression in
disease and development is now being studied, and although
changes in individual a chain message is being found in these
conditions, again the complexity of the biologic systems and
potential lack of specificity of assay systems remain problems.
In the future, these issues will be addressed along with the
specific function of the individual G protein subunits in signal-
ling systems.
The kidney
G proteins participate in many signalling pathways which are
common to all tissues. Unfortunately, establishing the function
of specific a chains in the kidney is beset with the same
problems as in other tissues. In the kidney, the problem is
compounded by the anatomic complexity of the organ, and the
large number of different cell types. These cell types may
differentially express G proteins with unique functions, but that
information is not yet available.
At this point, asking the importance of G proteins to the
kidney is a bit like asking the importance of cAMP or diacyl-
glycerol. To the extent that peptide hormones such as angio-
tensin II, PTH, and AVP, catecholamines such as epinephnne
and norepinephrine and other related small molecules regulate
functions in the kidney, G proteins are important. In many
tissues, such as nerve, muscle, and glands, ion channels regu-
late membrane potential and secretion, but in the distal nephron
they are important for maintaining electrolyte balance. If these
channels are directly regulated by G proteins, then G proteins
may be directly involved in regulating body fluid and electrolyte
status. Renal epithelial cells are polarized, and so may provide
a specialized tissue in which to study localization of second
messenger system components. So far, it is clear the G proteins
are present on both apical and basolateral membranes of the
proximal tubule, but it is not clear that important differences
between these two membranes exist, and much work remains to
be done, especially with increasing numbers of a chains appear-
ing rapidly.
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The diseases which can be attributed to abnormalities of G
protein function are limited. Primary pseudohypoparathy-
roidism, a genetic disease which results in failure of expression
of one allele of a, and consequently a low level of hormone-
dependent cAMP production in all tissues, has been well
described [911. Growth hormone-secreting pituitary tumors
contain a mutant a which results in a constitutively activated
cyclase system [17]. We will not be surprised to find other
tumors, which contain other a chains with mutations, given the
importance of G protein-dependent signalling pathways in
growth and differentiation. Many diseases such as hypertension
may be diseases of regulation—perhaps subtle errors in re-
sponse to a stimulus. To the extent that "dysregulation" is an
important mechanism of disease, an understanding of regula-
tory mechanisms—G proteins are an important one—will be a
fruitful field of study.
Reprint requests to R. Tyler Miller, M.D., Division of Nephrology,
University of Texas Southwestern Medical School, 5323 Harty Hines
Boulevard, Dallas, Texas 75231, USA.
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